ACTIVITY BY QUARTER (variation at current exchange rates)
thousands of euros
1st quarter
2nd quarter
2015
2016
Var. 16/15
2015
2016
Var. 16/15
France
89,584
90,494
+1.0%
76,864
80,469
+4.7%
Europe (excluding France)
40,657
43,685
+7.4%
29,943
31,572
+5.4%
North America
17,193
16,064
-6.6%
12,894
14,113
+9.5%
Other countries
4,622
3,846
-16.8%
3,816
4,061
+6.4%
Group total
152,056
154,089
+1.3%
123,517
130,215
+5.4%
thousands of euros
1st quarter
2nd quarter
2015
2016
Var. 16/15
2015
2016
Var. 16/15
Non-proprietary Homeopathic Medicines
79,191
80,147
+1.2%
74,354
76,001
+2.2%
OTC Specialties
72,880
73,743
+1.2%
49,030
53,719
+9.6%
Other
-15
199
-
133
495
+272.2%
Group total
152,056
154,089
+1.3%
123,517
130,215
+5.4%
HIGHLIGHTS OF THE SECOND QUARTER 2016
Despite a negative impact of the evolution of the Rouble and, to a lesser extent, of the Dollar, sales in the second quarter of 2016 rose by 5.4% (+7.3% at constant exchange rate) in comparison to the 2015 second quarter.
Activity is growing in most countries, except in Spain and Italy.
Operational income in the first half of 2016 should rise in comparison to 2015.
In the USA, the last class action procedure against the medicine Oscillococcinum® has been rejected unanimously by the jury of the Los Angeles Court in California. This verdict may be appealed.
In Canada, the federal department of health, Health Canada, got back on its statements of the end of July 2015 and authorizes to maintain the indications of use on medicines against cough, cold and flu for children under 12. By March 31, 2017, a claim on the packaging must state the grounds of such allegations.
Our company continues with the same passion the development of homeopathy in the world.
Our next update:
September 8, 2016: at market close, publication of 2016 half-year results.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA
The group's financial information is online at: www.boironfinance.com
Regulated information
Releases under ongoing disclosure requirements:
- Permanent Information Releases, sales and Revenues
Full and original press release in PDF:
https://www.actusnews.com/documents_communiques/ACTUS-0-45019-BOI-190716-CA-T2-16-GB.pdf
Receive by email the next press releases of the company by registering on
www.actusnews.com, it′s free
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (52.4%), Europe (22.5%), North America (22.6%) and other (2.5%).
BOIRON 
